Nadroparin cardiovascular data

In the double-blind PROTECHT study in 1,166 cancer patients, once-daily subcutaneous nadroparin met the primary endpoint of significantly fewer thromboembolic events vs. placebo (2.1% vs. 3.9%, p=0.03...